Does Max Healthcare’s Pune Entry Strengthen Its Growth Moat
About the Goldman Sachs View
Goldman Sachs has maintained a Buy rating on Max Healthcare with a target price of ₹1,325, citing strategic expansion into Pune through a large greenfield hospital project.
The board approved acquisition of 100 percent equity in Yerawada Properties Pvt Ltd, enabling development of a ~450-bed super specialty hospital with total investment of up to ₹1,020 crore.
Hospital Sector – Peer Comparison
| Company | Expansion Strategy | City Focus |
|---|---|---|
| Max Healthcare | Greenfield | Pune |
| Apollo Hospitals | Asset-light + Brownfield | Pan-India |
| Narayana Health | Cost-led | Tier 2/3 |
👉 Healthcare stocks often see steady accumulation during market consolidations tracked via BankNifty Tip.
Investor Takeaway: Entry into Pune strengthens Max Healthcare’s metro footprint and long-term earnings visibility. Follow such secular healthcare stories at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
SEBI Disclaimer: The information provided is for informational purposes only and should not be construed as investment advice.











